Development of an in vitro model for vascular injury with human endothelial cells

Altex

Volumn 21, Issue SUPPL. 3, 2004, Pages 12-19

  Schleger, Claudia ^a   Platz, Stefan J ^a   Deschl, Ulrich ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Cytotoxicity; Endothelial cells; HUVEC; In vitro; Transendothelial permeability

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMRINONE; CYCLOSPORIN A; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; MENADIONE; MITOMYCIN C; PROSTACYCLIN; PROSTAGLANDIN; ROLIPRAM; THROMBOXANE;

ARTICLE; BIOASSAY; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CELL FUNCTION; CELL SPECIFICITY; CELL STRAIN 3T3; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SCREENING; ENDOTHELIUM CELL; GENE LOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER VENOOCCLUSIVE DISEASE; SENSITIVITY ANALYSIS; UMBILICAL VEIN; VASCULAR RESISTANCE; VASCULITIS; VASOCONSTRICTION;

3T3 CELLS; AMRINONE; ANIMAL TESTING ALTERNATIVES; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIFIBRINOLYTIC AGENTS; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CELLS, CULTURED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MICE; MITOMYCIN; MODELS, BIOLOGICAL; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; THROMBOXANE A2; UMBILICAL VEINS; VITAMIN K 3;

EID: 3242797413     PISSN: 09467785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Akman, S., Carr, B., Leong, L. et al. (1988). Phase I Trial of Menadiol Sodium Diphosphate (Synkavite) (M) in Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 7, 24 Meet., 76.
2. Barchowsky, A., Tabrizi, K., Kent, R. S. and Whorton, A. R. (1989). Inhibition of prostaglandin synthesis after metabolism of menadione by cultured porcine endothelial cells. J. Clin. Invest. 83, 1153-1159.
3. Boor, P. J., Gottlieb, A. I., Joseph, E. C. et al. (1993). Chemical-induced vasculature injury. Summary of the symposium presented at the 32nd annual meeting of the Society of Toxicology, New Orleans, Louisiana, March 1993. Toxicol. Appl. Pharmacol. 132, 177-195.
4. Clemedson, C. and Ekwall, B. (1999). Overview of the final MEIC results: I. The in vitro-in vivo evaluation. Toxicol. In Vitro 13, 657-663.
5. Dye, J. F., Leach, L., Clark, P. and Firth, J. A. (2001). Cyclic AMP and acidic fibroblast growth factor have opposing effects on tight and adherens junctions in microvascular endothelial cells in vitro. Microvasc. Res. 62, 94-113.
6. EMEA (2001). Note for guidance on non-clinical local tolerance testing of medicinal products (CPMP/SWP/2145/00) of The European Agency for the Evaluation of Medicinal Products.
7. Hoorn, C. M., Wagner, J. G., Petry, T. W. and Roth, R. A. (1995). Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol. 130, 87-94.
8. Idris, I., Gray, S., Donnelly, R. (2003). Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 46, 288-290.
9. Jiang, W. G., Martin, T. A., Matsumoto, K. et al. (1999). Hepatocyte growth factor/scatter factor decreases the expression of occludin and transendothelial resistance (TER) and increases paracellular permeability in human vascular endothelial cells. J. Cell. Physiol. 181, 319-329.
10. Joseph, E. C., Rees, J. A. and Dayan, A. D. (1996). Mesenteric arteriopathy in the rat induced by phosphodiesterase III inhibitors: an investigation of morphological, ultrastructural, and hemodynamic changes. Toxicol. Pathol. 24, 436-450.
11. Karanes, C., Ratanatharathorn, V., Schilcher, R. B. et al. (1986). High-Dose Mitomycin-C with Autologous Bone Marrow Transplantation in Patients with Refractory Malignancies. Influence of Dose Schedule on Pharmacokinetics and Nonhematopoietic Toxicities. Am. J. Clin. Oncol. Cancer Clin. Trials 9, 444-448.
12. Lagrange, P., Romero, I. A., Minn, A. and Revest, P. A. (1999). Transendothelial permeability changes induced by free radicals in an in vitro model of the blood-brain barrier. Free Radic. Biol. Med. 27, 667-672.
13. Larson, J. L., Pino, M. V., Geiger, L. E. and Simeone, C. R. (1996). The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78, 44-49.
14. Lau, D. C., Wong, K. L. and Hwang, W. S. (1989). Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int. 35, 604-613.
15. Lazarus, H. M., Gottfried, M. R., Herzig, R. H. et al. (1982). Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 49, 1789-1795.
16. Lee, J. Y., Lee, M. Y., Chung, S. M. and Chung, J. H. (1999). Menadione-induced vascular endothelial dysfunction and its possible significance. Toxicol. Appl. Pharmacol. 161, 140-145.
17. Mason, J. (1990). Pharmacology of cyclosporine (sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev. 41, 423-434.
18. McAmis, W. C., Schaeffer, R. C. Jr., Baynes, J. W. and Wolf, M. B. (2003). Menadione causes endothelial barrier failure by a direct effect on intracellular thiols, independent of reactive oxidant production. Biochim. Biophys. Acta 1641, 43-53.
19. Moncada, S. and Vane, J. R. (1978). Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 30, 293-331.
20. Oriji, G. K. and Schanz, N. (2001). Nitric oxide in CsA-induced hypertension: role of beta-adrenoceptor antagonist and thromboxane A2. Prostaglandins Leukot. Essent. Fatty Acids 65, 259-263.
21. Ortiz, J. L., Cortijo, J., Valles, J. M. and Morcillo, E. J. (1992). Rolipram inhibits PAF-induced airway microvascular leakage in guinea-pig: a comparison with milrinone and theophylline. Fundam. Clin. Pharmacol. 6, 247-249.
22. Remuzzi, G. and Bertani, T. (1989). Renal vascular and thrombotic effects of cyclosporine. Am. J. Kidney Dis. 13, 261-272.
23. Rutten, M. J., Hoover, R. L. and Karnovsky, M. J. (1987). Electrical resistance and macromolecular permeability of brain endothelial monolayer cultures. Brain Res. 425, 301-310.
24. Tervaert, J. W. and Kallenberg, C. G. (1997). Cell adhesion molecules in vasculitis. Curr. Opin. Rheumatol. 9, 16-25.
25. Schilcher, R. B., Young, J. D., Ratanatharathorn, V. et al. (1984). Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother. Pharmacol. 13, 186-90.
26. Vicart, P., Testut, P., Schwartz, B. et al. (1993). Cell adhesion markers are expressed by a stable human endothelial cell line transformed by the SV40 large T antigen under vimentin promoter control. J. Cell Physiol. 157, 41-51.
27. Voss, B. L., Hamilton, K. K., Samara, E. N. and McKee, P. A. (1988). Cyclosporine suppression of endothelial prostacyclin generation. A possible mechanism for nephrotoxicity. Transplantation 45, 793-796.
28. Wautier, M. P., Chappey, O., Vicart, P. et al. (1999). Immortalized human endothelial cells have a decreased response to IL-1 secondary to an IL-1 receptor defective expression restored by corticosteroids. Cell Biol. Toxicol. 15, 153-161.